Karen Wagner, PhD
General Partner - Ysios Capital
Dr Karen Wagner is a senior executive and entrepreneur with close to 20 years experience in the biopharmaceutical industry. Karen is General Partner at Ysios Capital Partners and her main role at Ysios is to identify and manage therapeutic investments.
Prior to joining Ysios in 2008, Karen was a Global Alliance Director for F. Hoffmann-La Roche in Basel, Switzerland. Among other transactions, she was project leader for the Alnylam-Roche collaboration announced in July 2007, valued at over $1 billion and one of Allicense’s Key Deals of the year. She joined Roche from GLYCART, a biotech company in the antibody engineering space, where she was head of business development. GLYCART was acquired by Roche in 2005 for 235 million Swiss Francs. Karen has also worked as a consultant and was a member of McKinsey & Company’s Global Healthcare Practice.
In addition to Vivet, Karen serves as Chair on the Board of Aelix Therapeutics and is observer on the Boards of Minoryx Therapeutics and Kala Pharmaceuticals. Formerly, she was board member at Cardoz.
She holds a master’s degree in Molecular Biology and a PhD in Cell Biology, both from the University of Konstanz, Germany.